Leaderboards/Vascular Anomalies and Treatments

Vascular Anomalies and Treatments

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Lizhen Liu
The University of Sydney
2
Ifeyinwa E. Obiorah
University of Virginia Health System
3
Ava Diarra
Centre Hospitalier de Tourcoing
4
Hyojin Park
Yale University
5
Thomas Barba
Hospices Civils de Lyon
6
Caroline T. Seebauer
Luzerner Kantonsspital
7
Frederik Staels
AZ Maria Middelares
8
Stefanie Marek‐Iannucci
Sapienza University of Rome
9
Tala Al Tabosh
Université de Bordeaux
10
Carmelo Gurnari
University of Rome Tor Vergata

Rising Stars Papers

1
Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances
Journal of Clinical Investigation|2024
64 cit.
2
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
Blood Advances|2024
61 cit.
3
Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors
Angiogenesis|2024
22 cit.
4
Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis
Blood|2024
21 cit.
5
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT
Blood|2025
18 cit.
6
Methodology and clinical utility of longitudinal <scp><i>UBA1</i></scp> tracking in <scp>VEXAS</scp> syndrome
British Journal of Haematology|2024
10 cit.
7
Ratiometric fluorescence and smartphone-assisted sensing platform based on dual-emission carbon dots for brilliant blue detection
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy|2024
7 cit.
8
Bleomycin Electrosclerotherapy (BEST) for Slow-Flow Malformations of the Upper Aerodigestive Tract
Biomedicines|2025
7 cit.
9
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study
Leukemia|2025
7 cit.
10
Chemotaxis overrides the killing response in alloreactive CTLs, providing vascular immune privilege during cellular rejection
Journal of Clinical Investigation|2025
6 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Hongjian Yu
Yangzhou University
2
Stryder M. Meadows
Tulane University
3
Antoni Riera‐Mestre
Institut d'Investigació Biomédica de Bellvitge
4
Taskin M. Monjur
American Academy of Otolaryngology — Head and Neck Surgery
5
Hanny Al‐Samkari
Harvard University
6
Jamie McDonald
University of Utah
7
David Vizcaya
Bayer (Germany)
8
Peter J. Leary
University of Washington
9
Liang Wu
Yangzhou University
10
Zhengping Li
Anhui University

Emerging Leaders Papers

1
Clinical Practice Guideline: Tympanostomy Tubes in Children (Update)
Otolaryngology|2022
167 cit.
2
Mitapivat versus Placebo for Pyruvate Kinase Deficiency
New England Journal of Medicine|2022
94 cit.
3
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
British Journal of Haematology|2022
78 cit.
4
Enhanced piezo-photocatalytic performance in ZnIn2S4/BiFeO3 heterojunction stimulated by solar and mechanical energy for efficient hydrogen evolution
Journal of Colloid and Interface Science|2024
78 cit.
5
In situ reversible assembly of atomic interfacial structure in BiOI/Bi5O7I p-n heterojunctions to promote visible-light photocatalysis
Chemical Engineering Journal|2023
52 cit.
6
A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies
Journal of Thrombosis and Haemostasis|2022
39 cit.
7
Recent advances in the effects of dietary polyphenols on inflammation in vivo: potential molecular mechanisms, receptor targets, safety issues, and uses of nanodelivery system and polyphenol polymers
Current Opinion in Food Science|2022
37 cit.
8
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
New England Journal of Medicine|2024
36 cit.
9
Short-Chain Fatty Acids Weaken Ox-LDL-Induced Cell Inflammatory Injury by Inhibiting the NLRP3/Caspase-1 Pathway and Affecting Cellular Metabolism in THP-1 Cells
Molecules|2022
29 cit.
10
Macroscopic polarization enhancement boosting piezo-photocatalytic performance via Nb-doping on B-site of Bi <sub>4</sub>Ti <sub>3</sub>O <sub>12</sub> nanosheets
Journal of Advanced Ceramics|2024
29 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Douglas A. Marchuk
Duke University
2
John Varga
Michigan Medicine
3
Michelle Letarte
University of Toronto
4
Marc Humbert
Inserm
5
Lewis J. Rubin
University of California San Diego
6
Sabine Bailly
Inserm
7
Carmelo Bernabéu
National Research Council
8
Marie E. Faughnan
St. Michael's Hospital
9
S. Paul Oh
CHA University
10
Claire L. Shovlin
Imperial College Healthcare NHS Trust

Current Senior Leaders Papers

1
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
European Heart Journal|2022
3.7k cit.
2
Bosentan Therapy for Pulmonary Arterial Hypertension
New England Journal of Medicine|2002
2.7k cit.
3
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
Journal of the American College of Cardiology|2009
2.4k cit.
4
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
European Respiratory Journal|2022
2.1k cit.
5
Pulmonary Arterial Hypertension in France
American Journal of Respiratory and Critical Care Medicine|2006
2k cit.
6
Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)
American Journal of Medical Genetics|2000
1.7k cit.
7
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
The Lancet|2001
1.5k cit.
8
Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1
Nature Genetics|1994
1.5k cit.
9
Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension: A Double-blind, Randomized, Placebo-controlled Trial
American Journal of Respiratory and Critical Care Medicine|2002
1.4k cit.
10
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
Circulation|2010
1.4k cit.

Reagents for Vascular Anomalies and Treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Cell Signaling TechnologyEvidence 66

PhosphoPlus® beta-Catenin (Ser675) Antibody Duet

#11887$730
View Evidence →
Cell Signaling TechnologyEvidence 61

Langerin (D9H7R) Rabbit Monoclonal Antibody

#13650$161,384
View Evidence →

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

Phospho-ATF-2 (Thr71)/ATF-7 (Thr53) (A8J7P) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

#20534$493
View Evidence →
Cell Signaling Technology

Rab Family Antibody Sampler Kit

#9385$509
View Evidence →
Cell Signaling TechnologyEvidence 66

Cyclin A2 (E1D9T) Rabbit Monoclonal Antibody

#91500$161,351
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Total ApoE Matched Antibody Pair

#98646$1,726
View Evidence →
Cell Signaling TechnologyEvidence 66

PhosphoPlus® beta-Catenin (Ser675) Antibody Duet

#11887$730
View Evidence →
Cell Signaling Technology

Human/Mouse/Rat Activin A Recombinant Protein

#27313$245
View Evidence →